Treatment of Crohn's Disease and Concomitant Alopecia Areata With Tofacitinib

The document discusses a case of a 37-year-old woman with Crohn's disease who developed Alopecia Areata (AA), which progressed to alopecia totalis and universalis while on adalimumab treatment. The patient was then successfully treated for AA with tofacitinib, a Janus kinase 1/3 inhibitor, which also maintained her Crohn's disease. The study suggests a possible shared molecular pathway between AA and inflammatory bowel disease. It also notes that tumor necrosis factor-alpha antagonists, often used in inflammatory bowel disease treatment, can sometimes cause new-onset AA. The study concludes that tofacitinib effectively treated AA in a patient with Crohn's disease previously treated with adalimumab.